ReviewCurrent infectious disease reports2018
Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention.
Review in Current infectious disease reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Fluoroquinolone-Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real-World Data From FAERS (2011-2024).Pharmacology research & perspectives · 2026Article
- Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.Frontiers in cellular and infection microbiology · 2026Article
- The Potential of Lactic Acid Bacteria and Dairy By-Products in ControllingMicroorganisms · 2025Review
- Impact of a multimodal antimicrobial stewardship intervention on fluoroquinolone usage for antimicrobial prophylaxis before urologic procedures in a Veterans Affairs outpatient clinic.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Assessing antimicrobial consumption in public and private sectors within the Costa Rican health system: current status and future directions.BMC public health · 2024Observational
- Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.Microbiology spectrum · 2024Article
- Identifying targets for antibiotic stewardship interventions in pediatric patients in Punjab, Pakistan: point prevalence surveys using AWaRe guidance.Frontiers in pediatrics · 2024Article
- Hospital antimicrobial stewardship funding and resourcing impact on broad-spectrum antibiotic use: a cross-sectional study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Exploring drivers and challenges influencing antibiotic prescribing in outpatient settings and possible mitigation strategies in the United Arab Emirates: a qualitative study.JAC-antimicrobial resistance · 2023Article
- Impact of prolonged carbapenem use-focused antimicrobial stewardship on antimicrobial consumption and factors affecting acceptance of recommendations: a quasi-experimental study.Scientific reports · 2023Article
- Comparison of Different Antibiotics and the Risk for Community-AssociatedOpen forum infectious diseases · 2023Article
- Do or Don't: Results of a Multinational Survey on Antibiotic Prophylaxis in Urodynamics.Antibiotics (Basel, Switzerland) · 2023Article
- Impact of a Primary Care Antimicrobial Stewardship Program on Bacterial Resistance Control and Ecological Imprint in Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2022Article
- Attitudes towards Use of High-Importance Antimicrobials-A Cross-Sectional Study of Australian Veterinarians.Antibiotics (Basel, Switzerland) · 2022Article
- A Nonrestrictive Approach to Fluoroquinolone Stewardship at Two Community Hospitals.Open forum infectious diseases · 2022Article
- Impact of an empiric antimicrobial therapy manual on antimicrobial usage and multidrug resistant organism trends in a large Italian teaching hospital.Infection prevention in practice · 2022Article
- The Kinetics of an Antibiotic Stewardship Intervention: A Quasi-Experimental Study.Infectious diseases and therapy · 2021Article
- Impact of an Antibiotic Stewardship Program on the Incidence of ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural Chelocardin.Antibiotics (Basel, Switzerland) · 2020Article
- Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFluoroquinolones are a commonly prescribed antibiotic class that has come under scrutiny in recent years due to mounting evidence of association between adverse drug events, C. difficile infection and isolation of antibiotic-resistant bacteria. RECENT
findingsInpatient antimicrobial stewardship (AMS) programs have a toolbox of potential interventions to curb inappropriate antibiotic use, prevent antibiotic-associated adverse drug events, and avoid unnecessary costs of care. Fluoroquinolone restriction policies in the acute care setting have demonstrated beneficial effects, including decreased rates of C. difficile infection and ESBL-producing Enterobacteriaceae. However, a simple blanket restriction policy may "squeeze the antibiotic balloon" and will likely be insufficient if not implemented in conjunction with other AMS interventions. There is a growing body of evidence to support formulary restriction of fluoroquinolones in the acute care setting to decrease rates of C. difficile infection and development of ESBL-producing organisms. Data on how to best implement these restrictions or how to implement outside of acute care settings is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.